Manoj Waikar
Psychiatry · Los Gatos, CANPI 1821150574
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,442,268 of the $1,890,800 with a category attached, or 76.3%. 23 manufacturers reported payments, led by Alkermes, Inc. at 38.2% of the total. 2025 is the largest year on record at $413,164, 2.1 times the $200,161 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,650 payments — averaging $713.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$722K
- AbbVie$370K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$356K
- Teva Pharmaceuticals USA, Inc.$171K
- Axsome Therapeutics, Inc.$104K
- Vanda Pharmaceuticals Inc.$74K
- plus $95K from 17 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$1K
What the payments were for
- Consulting fees$73,3684%
- Speaking & faculty fees$1,442,26876%
- Travel & lodging$320,86117%
- Food & beverage$54,1843%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 976 | $721,504 |
| AbbVie(2 entities) | 518 | $370,060 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 415 | $355,603 |
| Teva Pharmaceuticals USA, Inc. | 179 | $170,562 |
| Axsome Therapeutics, Inc. | 176 | $104,085 |
| Vanda Pharmaceuticals Inc. | 115 | $74,183 |
| Neurocrine Biosciences, Inc. | 106 | $47,567 |
| E.r. Squibb & Sons, L.L.C. | 63 | $30,791 |
| Otsuka America Pharmaceutical, Inc. | 14 | $8,411 |
| Luye Pharma (USA) Ltd. | 4 | $4,664 |
| Acadia Pharmaceuticals Inc | 21 | $1,552 |
| Johnson & Johnson | 11 | $464 |
| Eisai Inc. | 17 | $411 |
| Jazz Pharmaceuticals Inc. | 13 | $393 |
| Harmony Biosciences LLC | 6 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Idorsia Pharmaceuticals US Inc | 5 | $100 |
| Resmed Corp | 1 | $27 |
| Merck | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Indivior Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,890,800 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $18,359 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,500 |
| DayvigoLemborexant | 12 | $3,791 |
| Ziprasidone Hcl | 26 | $650 |
| Bupropion Hcl SrBupropion Hcl | 12 | $201 |
| Trazodone Hcl | 14 | $76 |
| Duloxetine Hcl | 13 | $60 |
| Buspirone Hcl | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $370,060 | $18,35913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $124 | $5,50012 claims |
| Eisai Inc.Dayvigo | $411 | $3,79112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Los Gatos
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
- Jason BermakSan Rafael$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.